Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in adults older than 50 years. We aimed to determine whether intradermal administration of zoster vaccine could enhance vaccine immunogenicity compared with conventional needle subcutaneous administration.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Infect Dis

Title: The Lancet. Infectious diseases

Publisher: Elsevier BV

ISSN (Electronic): 1474-4457

ISSN (Print): 1473-3099

Publication date (Electronic): August 2016

Volume: 16

Issue: 8

Affiliations

[1 ] Merck & Co, Kenilworth, NJ, USA. Electronic address: chanbeals@gmail.com.

[2 ] Merck & Co, Kenilworth, NJ, USA.

[3 ] NanoPass Technologies Ltd, Nes Ziona, Israel.

[4 ] Miami Research Associates, Miami, FL, USA.

[5 ] Clinical Pharmacology of Miami, Miami, FL, USA.

[6 ] Pediatric Infectious Diseases, University of Colorado, Denver Anschutz Medical Campus, Aurora, CO, USA.

Article

Publisher Item ID: S1473-3099(16)00133-X

DOI: 10.1016/S1473-3099(16)00133-X

PubMed ID: 27061887

SO-VID: df352260-2b56-40c2-8c06-37a4755a3010

History

Data availability:

Comments

Comment on this article

scite_

Cited by 15

See all cited by

- Version 1